RxDoctor Payments Data

Jian Li, MD

Nephrology · Detroit, MINPI 1689864779

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 65.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for nephrology clinicians in MI, where the typical reported total is $606.

$184in general payments, 2019–2025

Across 2 payments — averaging $92.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$121
  • Novo Nordisk$63
$142,736in research payments, 2019–2025

Across 139 payments — averaging $1026.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Akebia Therapeutics Inc$143K

What the payments were for

  • Food & beverage$184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$121
Novo Nordisk1$63

How this compares

$184 in reported general payments places this provider in the 25th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$74,515
Medicare patients
218
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$43,203
FarxigaDapagliflozin Propanediol13$12,021
Sevelamer Carbonate17$2,909
Calcium Acetate28$2,701
Labetalol Hcl25$1,293
Nifedipine ErNifedipine36$1,076
Bumetanide17$735
Losartan Potassium35$242
Metoprolol Succinate11$143
Carvedilol32$128
Spironolactone11$110
Atorvastatin Calcium15$89
Amlodipine Besylate12$65
Vitamin D2Ergocalciferol (Vitamin D2)15$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$121$12,02113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 325 nephrology providers in Michigan.

Other nephrology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →